芬兰全国双相障碍队列中药物治疗预防再住院的真实世界有效性
结果显示碳酸锂与长效注射剂分别作为心境稳定剂和抗精神病药中预防精神科或躯体疾病再住院最有效的选择。
要点
- 碳酸锂与精神科再住院风险降低相关(HR 0.67,95%CI 0.60-0.73),为心境稳定剂中最有效。
- 长效注射剂较相同口服抗精神病药显著降低精神科再住院风险(HR 0.70,95%CI 0.55-0.90)。
- 喹硫平富马酸盐仅显示 modest 效果,精神科再住院风险 HR 0.92(95%CI 0.85-0.98)。
核心结论
- 碳酸锂是预防精神科或躯体疾病再住院最有效的心境稳定剂,长效注射剂是最有效的抗精神病药。
主要发现
- 54.0%的患者(9721例)至少经历1次精神科再住院。
- 利培酮长效注射剂(HR 0.58,95%CI 0.34-1.00)、加巴喷丁(HR 0.58,95%CI 0.44-0.77)、奋乃静长效注射剂(HR 0.60,95%CI 0.41-0.88)和碳酸锂(HR 0.67,95%CI 0.60-0.73)与最低的精神科再住院风险相关。
- 碳酸锂与最低的全因住院风险相关(HR 0.71,95%CI 0.66-0.76)。
- 长效注射剂较相同口服抗精神病药在全因住院风险上更优(HR 0.70,95%CI 0.57-0.86)。
- 敏感性分析显示仅碳酸锂和长效注射剂(较口服剂型)具有一致的有益效应。
关键数值与推荐
- 精神科再住院风险:利培酮长效注射剂 HR 0.58(95%CI 0.34-1.00),加巴喷丁 HR 0.58(95%CI 0.44-0.77),奋乃静长效注射剂 HR 0.60(95%CI 0.41-0.88),碳酸锂 HR 0.67(95%CI 0.60-0.73)。
- 全因住院风险:碳酸锂 HR 0.71(95%CI 0.66-0.76),喹硫平富马酸盐 HR 0.93(95%CI 0.88-0.98)。
- 长效注射剂 vs 相同口服抗精神病药:精神科再住院 HR 0.70(95%CI 0.55-0.90),全因住院 HR 0.70(95%CI 0.57-0.86)。
临床怎么用
- 在双相障碍维持治疗中,碳酸锂应作为优先考虑的心境稳定剂以降低再住院风险。
- 需使用抗精神病药时,长效注射剂型可能较口服剂型更有效预防再住院。
- 喹硫平富马酸盐虽常用,但预防再住院效果相对有限,临床决策需权衡。
局限性
- 观察性研究设计,尽管采用个体内分析,仍可能存在残余混杂。
- 仅纳入因双相障碍住院的患者,结果外推至门诊或轻症患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mood stabilizers and antipsychotics are the main maintenance treatments for bipolar disorder. Lithium is considered to be the most effective mood stabilizer, but very little is known about overall health outcomes associated with specific treatments and the comparative long-term effectiveness of specific psychotropics or routes of administration in the prevention of rehospitalizations. OBJECTIVE: To study the comparative effectiveness of pharmacologic treatments in the prevention of rehospitalization in a nationwide cohort of patients with bipolar disorder. DESIGN, SETTING, AND PARTICIPANTS: This cohort study examined the risk of psychiatric, cardiovascular, and all-cause hospitalization from January 1, 1987, to December 31, 2012, among all patients in Finland who had been hospitalized for bipolar disorder (N = 18 018; mean follow-up time, 7.2 years) using prospectively gathered nationwide databases for hospitalization and dispensed medications. The primary analysis was within-individual analysis, in which each individual was used as his or her own control to eliminate selection bias. The study adjusted for the effect of concomitant psychotropic medications, duration of illness, and the temporal orders of exposure and nonexposure periods. Statistical analysis was conducted from January 1, 1996, to December 31, 2012. MAIN OUTCOMES AND MEASURES: Adjusted hazard ratios (HRs) for rehospitalization were calculated. RESULTS: Among the cohort (9558 women and 8460 men; mean [SD] age, 46.6 [17.0] years), 9721 patients (54.0%) had at least 1 psychiatric rehospitalization. In comparison between use and no use among specific agents reaching nominal statistical significance, risperidone long-acting injection (HR, 0.58 [95% CI, 0.34-1.00]), gabapentin (HR, 0.58 [95% CI, 0.44-0.77]), perphenazine long-acting injection (HR, 0.60 [95% CI, 0.41-0.88]), and lithium carbonate (HR, 0.67 [95% CI, 0.60-0.73]) were associated with the lowest risk of psychiatric rehospitalization. Concerning all-cause hospitalization, lithium (HR, 0.71 [95% CI, 0.66-0.76]) was associated with the lowest risk. The most frequently used antipsychotic treatment, quetiapine fumarate, showed only modest effectiveness (risk of psychiatric rehospitalization: HR, 0.92 [95% CI, 0.85-0.98]; risk of all-cause hospitalization: HR, 0.93 [95% CI, 0.88-0.98]). Long-acting injections were associated with substantially better outcomes compared with identical oral antipsychotics (risk of psychiatric rehospitalization: HR, 0.70 [95% CI, 0.55-0.90]; risk of all-cause hospitalization: HR, 0.70 [95% CI, 0.57-0.86]). Results from sensitivity analyses showed consistent beneficial effects only for lithium and for long-acting injections compared with their oral counterparts. CONCLUSIONS AND RELEVANCE: Lithium was the most effective mood stabilizer, and long-acting injections the most effective antipsychotics, in preventing hospitalization due to mental or physical illness.
引用
- Lähteenvuo M, Tanskanen A, Taipale H, et al. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry. 2018. PMID: 29490359. doi:10.1001/jamapsychiatry.2017.4711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。